HTA60 Icosapent Ethyl in Addition to Statins Is a Cost-Effective Treatment in Patients at High Cardiovascular Risk With Elevated Triglycerides and Established Cardiovascular Disease or Diabetes With Risk Factor in the Netherlands

Autor:	Pronk, LM, Piena, M, Van de Pas, M, Jakouloff, D, Giesen, E
Zdroj:	In Value in Health December 2022 25(12) Supplement:S308-S308
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect